LENZ Therapeutics Inc (NASDAQ:LENZ) shares, rose in value on Thursday, April 16, with the stock price up by 3.30% to the previous day’s close as strong demand from buyers drove the stock to $23.82.
Actively observing the price movement in the last trading, the stock closed the session at $23.06, falling within a range of $23.01 and $24.585. Referring to stock’s 52-week performance, its high was $38.93, and the low was $14.42. On the whole, LENZ has fluctuated by -6.66% over the past month.
With the market capitalization of LENZ Therapeutics Inc currently standing at about $656.07 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-18.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that LENZ’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of LENZ currently trading nearly 1.30% and 0.30% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 52.20, while the 7-day volatility ratio is showing 9.61% which for the 30-day chart, stands at 10.11%. Furthermore, LENZ Therapeutics Inc (LENZ)’s beta value is 0.56, and its average true range (ATR) is 2.19.
A comparison of LENZ Therapeutics Inc (LENZ) with its peers suggests the former has fared considerably weaker in the market. LENZ showed an intraday change of 3.30% in last session, and over the past year, it grew by 19.58%%.
Data on historical trading for LENZ Therapeutics Inc (NASDAQ:LENZ) indicates that the trading volumes over the past 10 days have averaged 0.36 and over the past 3 months, they’ve averaged 207.92K. According to company’s latest data on outstanding shares, there are 27.52 million shares outstanding.
Nearly 17.90% of LENZ Therapeutics Inc’s shares belong to company insiders and institutional investors own 79.08% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.51 million shares as on 2025-03-31, resulting in a short ratio of 10.01. According to the data, the short interest in LENZ Therapeutics Inc (LENZ) stood at 1739.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 2.55 million. The stock has fallen by -17.49% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LENZ stock heading into the next quarter.
